<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Q318 Spine Market Recap: Spine Hardware Market is Stabilizing

Posted by Julianne Burns on 1/2/19 12:02 PM

The Spine hardware market appears to be stabilizing.

SmartTRAK reports that results from a recent Leerink MEDACorp survey suggest that the US Spine market may be turning the corner, with hospital administrators reporting slightly improved case volume growth of 0.9% for Q318 vs 0.7% for Q2. This is consistent with Leerink’s intra-quarter checks and conversations at the North American Spine Society (NASS) 2018 Annual Meeting that the market...

Among the many topics covered in the Q318 Spine Market Recap are:

Read More

Topics: Orthopedics-Spine, Q318 Market Recaps

SmartTRAK's Top Blog Posts of 2018: Orthopedic, Wound and Neuro News & Analysis

Posted by Sharon O'Reilly on 1/2/19 5:00 AM

BioMedGPS is proud to feature the top 2018 news and analysis from SmartTRAK’s team of domain exports in the orthopedics, wound care, and neuro therapies markets.


Read More

Topics: Computer Assisted Surgery - Ortho, Neurotherapies

SmartTRAK Cited in Smith & Nephew Meniscal Repair Press Release

Posted by Kristina Meyer on 12/20/18 9:30 AM

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands opportunity in meniscal repair through acquisition of unique and highly complementary technology."

Read More

Topics: Orthopedics-OrthoBio

SmartTRAK's Top Blog Posts of 2018

Posted by Sharon O'Reilly on 12/17/18 10:55 AM

We covered a lot of ground in 2018. Everything from breaking medical device event coverage to interviews with some of the industry's top thought leaders.  We wrote and you read.  Here are the Top Blog Posts of 2018 that garnered the most attention from you and your colleagues.

As a reminder, if you'd like to stay on top of hot trends and technologies in the ortho, wound and neuro markets, make sure to sign up to receive a weekly summary of our latest blog posts.

Without further ado, SmartTRAK's 12 Top Blog Posts of the past year (not just 10, because at SmartTRAK, we always deliver more than expected) 

Read More

Topics: Your SmartTRAK News

Q318 OrthoBio Market Recap: Acquisitions and Partnerships Rule

Posted by Kim French on 12/14/18 2:28 PM

Acquisitions and Partnerships are Highpoints in Q318

SmartTRAK reports that the US OrthoBio Market (comprised of Bone Replacement, Cartilage, Soft Tissue and Meniscus) is growing at 4.1% YTD. For Q318, there were no surprises and the segment reached...

Among the many topics covered in the Q318 OrthoBio Market Recap are:

Read More

Topics: OrthoBio, Q318 Market Recaps

Q318 Advanced Wound Care Market Recap: All Segments Showing Softness

Posted by Susan Paquette on 12/13/18 1:54 PM

All segments showing softness, lowest quarterly growth rate since 2015

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +3.0% YoY, with Acelity, also known as KCI, maintaining its leadership position with estimated Q318 revenues of...

Read More

Topics: Advanced Wound Care, Q318 Market Recaps

SmartTRAK Attends OSET in Vegas Dec 5-8

Posted by Rebecca Gonzalez on 12/11/18 2:15 PM

SmartTRAK was excited to attend the 2018 Orthopaedic Summit (OSET), on December 5-8 at the Bellagio in Las Vegas, Nevada. And, our very own Kristina Meyer, Senior Analyst, Sports Medicine, landed on the front of the OSET banners. We always knew Kristina was a pretty big deal!  Thanks OSET for the coverage.

Read More

Topics: Orthopedics-Soft Tissue Fixation, Orthopedic

Q318 Joint Fluid Market Recap-Trending Downward Owing to Pricing Declines

Posted by Sharon O'Reilly on 12/5/18 9:55 AM

Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...

Read More

Topics: OrthoBio, OrthoBio-Joint Fluid, Q318 Market Recaps

Q318 Total Joints Market Recap: Easier Comps Drive Improved US Growth

Posted by Lisa Mahan on 12/4/18 9:00 AM

It’s no surprise that Q318 US revenue growth accelerated YoY when, for the same period last year, the US Total Joints Market experienced major market disruption from two major hurricanes which delayed procedures beyond the usual Q3 procedural slowdown. Industry analysts, including Cantor Fitzgerald’s Craig Bijou, report that US recon growth was relatively flat on a stacked two-year basis. From this perspective, SmartTRAK believes this trend confirms the market is not showing major signs of improvement or decline...

Among the many topics covered in detail in the Q318 Total Joints Market Recap are:

Read More

Topics: Orthopedics-Total Joints, Q318 Market Recaps

Preventing Peripheral IV Failure: The Next Big Thing

Posted by Susan Paquette on 11/26/18 4:21 PM

Products that prevent peripheral IV failures could be the next big thing in the market for vascular access adjunct products, a market opportunity valued at more than $600MM in the US alone, according to SmartTRAK estimates.

All eyes were on the high failure rate of peripheral IVs at the Association of Vascular Access (AVA) 2018 Annual Scientific Meeting, with speakers highlighting the 2015 article by Helm et al. “Accepted but Unacceptable: Peripheral IV Catheter Failure,” which estimates a PIV failure rate of 35% to 50% primarily caused by phlebitis, infiltration, occlusion/mechanical failure, dislodgment and infection. Failure is defined as the removal of the catheter prior to the end of its intended life or before the 72 to 96 hours previously used as a guideline. And with up to 90% of all hospitalized patients receiving a PIV, it is a standard but often overlooked procedure in the hospital.

The primary emphasis over the last 10 to 15 years has been the reduction of catheter-related bloodstream infections (CRBSIs) associated with central line catheters. Driving this focus has been CMS reimbursement penalties for hospital acquired central line bloodstream infections (CLABSIs). This new focus on PIVs could be exciting for manufacturers, especially those with adjunct vascular access products. Clinicians insert approximately 250 million PIVs every year in the US (assuming a 25% failure rate on first insertion), a market that is 25 times larger than the US market for central line catheters...

Download the "Next Big Thing in Vascular Access" article now...

Read More

Topics: Advanced Wound Care, Vascular

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts